A recent study showed patients with Down syndrome are more likely to develop hidradenitis suppurativa compared with individuals without Down syndrome. Corresponding author Raed Alhusayen, MBBS, MSCE, FRCPC, discussed these findings in an interview with The Dermatologist.
While anyone can present with rosacea, this condition is often underdiagnosed among patients with darker phototypes. Dr Susan Taylor shares her clinical pearls for identifying rosacea in patients with skin of color.
Crystal Aguh, MD, presented on alternative treatments for patients with hair loss who may not be responding to conventional therapies at the Skin of Color Update. She discussed important treatment considerations for managing hair loss in an interview with The Dermatologist.
Amy McMichael, MD, presented on photoprotection at the Skin of Color Update. She discussed hot topics and misunderstandings regarding sunscreen use among patients with skin of color in an interview with The Dermatologist.
Amy McMichael, MD, discussed some common types of alopecias, including ones known to predominately affect patients with skin of color, and shared important pitfalls to keep in mind when treating patients with hair loss.
Findings from two randomized, vehicle-controlled trials showed a nonsteroidal topical treatment effectively improved psoriasis, including in difficult-to-treat areas. Mark Lebwohl, MD, discussed the implications of these findings in an interview with The Dermatologist.
A recent systematic review analyzed the role of multidisciplinary clinics for the treatment of patients with psychocutaneous diseases, including delusional infestation. Corresponding author Mohammad Jafferany, MD, discussed these findings further in an interview with The Dermatologist.
Tuberous sclerosis complex (TSC) is a rare, multiorgan, genetic disease with many cutaneous findings. In an interview with The Dermatologist, Elizabeth Thiele, MD, PhD, director of the TSC Center at Harvard Medical School, discusses common cutaneous symptoms of this disease.
A recent study found clinical trials that assessed the safety and efficacy of atopic dermatitis treatment rarely included older adults, with some even excluding patients younger than 60 years. Corresponding author Aaron Drucker, MD, discussed these findings and the importance of including older adults in trials for clinical practice.